Publication: Metabolite V, an epoxide species, is a minor circulating metabolite in humans following a single oral dose of deflazacort
This research article, published in Pharmacology Research & Perspectives, investigates the plasma pharmacokinetics, metabolite profiles and their quantitative exposures in humans following a single oraldose of deflazacort
Human circulating metabolites of deflazacort following a single oral dose are presented
The influence of a single dose of oral deflazacort is discussed
Safety findings following a single oral dose of deflazacort are presented
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Kong R, Ma J, Beers B, et al. Pharmacol Res Perspect. 2020;8(6):e00677
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
If not, register below
GL-DMD-0442 | October 2021
Sign in or register to access exclusive content on this site
Some cookies are essential, others help us improve your experience by providing insights into how the website is used. Select one or more of the cookie types listed below, and then save your preferences. Refer to our Cookies Statement for more information.
Performance cookies, which help us measure the website’s performance and improve your experience. In using performance cookies we do not store any personal data, and only use the information collected through these cookies in aggregated and anonymised form.